Drug Trial News

RSS

Ventria completes VEN100 phase 2 trial on antibiotic-associated diarrhea

Ventria Bioscience has announced the successful completion of a phase 2 clinical trial of its lead therapeutic candidate, VEN100. The study was conducted by a team of investigators from the Department of Epidemiology, Division of Infectious Diseases, and Division of Geriatric Medicine at Johns Hopkins University.

5 Apr 2012

Oral fluoroquinolones increase risk of retinal detachment

In an analysis of a cohort that included nearly one million patients who had visited an ophthalmologist, patients who were taking oral fluoroquinolones had a higher risk of developing a retinal detachment, a serious eye condition, compared with nonusers, although the absolute risk was small, according to a study in the April 4 issue of JAMA.

4 Apr 2012

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

4 Apr 2012

MedImmune's quadrivalent flu vaccine may protect children

An intranasal vaccine that includes four weakened strains of influenza could do a better job in protecting children from the flu than current vaccines, Saint Louis University research shows.

4 Apr 2012

Combination of carboplatin, paclitaxel and RT3D shows promise against head and neck cancer

A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research.

4 Apr 2012

Amgen, UCB commence CDP7851/AMG 785 Phase 3 trial in postmenopausal osteoporosis

UCB and Amgen announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.

4 Apr 2012

Combination of gemcitabine and TH-302 improves survival in advanced pancreatic cancer

The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found.

4 Apr 2012

Topline results from GSK's seven of eight albiglutide Phase 3 studies on type 2 diabetes

Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that topline results have been received from seven of the eight Harmony Phase 3 studies investigating the use of albiglutide in type 2 diabetes.

4 Apr 2012

Lilly announces results of three preclinical studies that focus on c-MET receptor

Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.

3 Apr 2012

Funding shortfalls could hinder implementation of treatment as prevention strategies, Al Jazeera reports

Al Jazeera examines the administration of combination antiretroviral therapy (ART) worldwide, focusing on treatment as prevention (TasP), but says current funding levels are insufficient to implement the strategy.

3 Apr 2012

Onyx announces results from regorafenib Phase 3 trial on GIST

Onyx Pharmaceuticals, Inc. today announced results from the Phase 3 trial GRID (GIST – Regorafenib in Progressive Disease) evaluating the investigational compound regorafenib (BAY 73-4506), a Bayer-owned compound, for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.

3 Apr 2012

New data demonstrates anti-cancer activities of Oncoprex

New data demonstrating the anti-cancer activities of Oncoprex were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, IL. The study, "Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC" (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored by a team of investigators from The University of Texas MD Anderson Cancer Center.

3 Apr 2012

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Keryx Biopharmaceuticals, Inc. reported today that the Phase 3 "X-PECT" clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

3 Apr 2012

Positive outcome from AiCuris’ Letermovir phase 2b trial on HCMV infections

AiCuris announced today that data on the positive outcome of Letermovir (AIC246) tested in a phase 2b trial in transplant patients will be disclosed at several international meetings on behalf of the AIC246 study team.

3 Apr 2012

Merck announces data from ZOSTAVAX Phase III study on shingles

Merck, known as MSD outside the United States and Canada, announced today that data from the pivotal Phase III study with ZOSTAVAX(Zoster Vaccine Live) in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases.

3 Apr 2012

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.

2 Apr 2012

Ampio, Australian TGA reach agreement over Zertane submission plan

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it reached agreement with the Therapeutic Goods Administration, Canberra, Australia, on a plan of drug manufacture and quality control for Zertane and the overall plan for the preparation of Common Technical Documents for the draft registration submission expected to be filed in June 2012.

2 Apr 2012

Enrollment complete in Oncolytics REOLYSIN combination trial for head and neck cancers

Oncolytics Biotech Inc. announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).

2 Apr 2012

NanoViricides reports positive pre-IND meeting with USFDA for FluCide

NanoViricides, Inc. announced today that its previously announced pre-IND Meeting was held with the USFDA on March 29th, 2012, as scheduled. This pre-IND meeting focused on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.

2 Apr 2012

$Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint$

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Aeterna Zentaris Inc. today announced that the Phase 3 "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

2 Apr 2012

Drug Trial News

Ventria completes VEN100 phase 2 trial on antibiotic-associated diarrhea

Oral fluoroquinolones increase risk of retinal detachment

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

MedImmune's quadrivalent flu vaccine may protect children

Combination of carboplatin, paclitaxel and RT3D shows promise against head and neck cancer

Amgen, UCB commence CDP7851/AMG 785 Phase 3 trial in postmenopausal osteoporosis

Combination of gemcitabine and TH-302 improves survival in advanced pancreatic cancer

Topline results from GSK's seven of eight albiglutide Phase 3 studies on type 2 diabetes

Lilly announces results of three preclinical studies that focus on c-MET receptor

Funding shortfalls could hinder implementation of treatment as prevention strategies, Al Jazeera reports

Onyx announces results from regorafenib Phase 3 trial on GIST

New data demonstrates anti-cancer activities of Oncoprex

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Positive outcome from AiCuris’ Letermovir phase 2b trial on HCMV infections

Merck announces data from ZOSTAVAX Phase III study on shingles

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

Ampio, Australian TGA reach agreement over Zertane submission plan

Enrollment complete in Oncolytics REOLYSIN combination trial for head and neck cancers

NanoViricides reports positive pre-IND meeting with USFDA for FluCide

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News